Genitourinary Cancer
AMA PRA Category 1 Credits 1.00
CAMPEP Credits: 1.00
MDCB Credits: 1.00
Brian Baumann, MD
Springfield Clinic
Springfield, IL, United States
Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or with high-risk disease. There is considerable interest in using SBRT or brachytherapy in this patient population as well as interest in use of genomic risk stratification tools (e.g., Decipher assay) to make decisions on the use and duration of ADT. The NRG recently opened the first trial in unfavorable intermediate-risk disease, NRG GU 010, to explore the use of genomic risk stratification to identify patients who could be candidates for treatment de-intensification or treatment intensification with systemic therapy.
Speaker: Brian Baumann, MD – Springfield Clinic
Speaker: Daniel Spratt, MD – University Hospitals Seidman Cancer Center
Speaker: Neil Desai, MD – University of Texas Southwestern Medical Center
Speaker: Cynthia Menard, MD – University of Montreal Hospital (CHUM)
Speaker: Brian Baumann, MD – Springfield Clinic